SCHEMBL20913832

SCHEMBL20913832

CNC(=O)c1cc(C(=O)N[C@H]2[C@@H]3COC[C@@H]32)cc(C(=O)OC)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 20/20 0.62
TRIM24 O15164 1/20 0.42
BRD1 O95696 1/20 0.42
CCL2 P13500 1/20 0.42
DRD2 P14416 1/20 0.42
TAF1 P21675 1/20 0.42
DRD4 P21917 1/20 0.42
BRD2 P25440 1/20 0.42
DRD3 P35462 1/20 0.42
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42
BRPF1 P55201 1/20 0.42
EP300 Q09472 1/20 0.42
BPTF Q12830 1/20 0.42
BRD3 Q15059 1/20 0.42
BRDT Q58F21 1/20 0.42
ATAD2 Q6PL18 1/20 0.42
PBRM1 Q86U86 1/20 0.42
TAF1L Q8IZX4 1/20 0.42
CREBBP Q92793 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20913834 1.00 BRD4 (0.62) BRD4TRIM24BRD1CCL2DRD2
SCHEMBL22593122 1.00 BRD4 (0.62) BRD4TRIM24BRD1CCL2DRD2
SCHEMBL20913836 1.00 BRD4 (0.62) BRD4TRIM24BRD1CCL2DRD2
SCHEMBL19448402 0.88 BRD4 (0.61) BRD4TRIM24BRD1CCL2DRD2
SCHEMBL20913846 0.88 BRD4 (0.61) BRD4TRIM24BRD1CCL2DRD2
SCHEMBL20913847 0.88 BRD4 (0.61) BRD4TRIM24BRD1CCL2DRD2
SCHEMBL19448404 0.85 BRD4 (0.65) BRD4
SCHEMBL22593123 0.83 BRD4 (0.58) BRD4TRIM24BRD1CCL2DRD2
SCHEMBL19448494 0.81 BRD4 (0.64) BRD4
SCHEMBL19448574 0.81 BRD4 (0.74) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 US disclosed
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 US disclosed
EP-3440069-B1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-10-28 EP disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 US disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors BRD4, BRD3, BRDT BRD4 1/4885TRIM24 2372/4885BRD1 6/4885
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT BRD4 1/4885TRIM24 2372/4885BRD1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.